IROC works to ensure sites participating in National Cancer Institute (NCI)-sponsored trials have adequate quality assurance (QA) procedures in place and no major systematic dosimetry discrepancies. The goal is for all sites to deliver clinically comparable radiotherapy treatment. Additionally, the NCI clinical trial research groups initiate protocols that use new technologies and treatment techniques. IROC develops and implements credentialing processes to ensure the research sites understand the study protocol and can treat patients according to a protocol's specifications.